F Rinaldi

Summary

Publications

  1. doi request reprint Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
    Francesca Rinaldi
    Multiple Sclerosis Centre of Veneto Region of Italy, Department of Neuroscience, University Hospital of Padova, Padova, Italy
    Mult Scler 15:1359-62. 2009
  2. doi request reprint Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report
    F Rinaldi
    Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Via Giustiniani 5, 35128, Padua, Italy
    Neurol Sci 31:317-20. 2011
  3. doi request reprint Cortical lesions and cognitive impairment in multiple sclerosis
    F Rinaldi
    Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Padua, Italy
    Neurol Sci 31:S235-7. 2010
  4. doi request reprint Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study
    M Calabrese
    Multiple Sclerosis Centre, First Neurology Clinic, University of Padova, Via Giustiniani 5, Padova 35128, Italy
    J Neurol Neurosurg Psychiatry 83:49-54. 2012
  5. doi request reprint Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    M Calabrese
    The Multiple Sclerosis Centre of the Veneto Region, Department of Neurology, University Hospital of Padova, Padova, Italy
    Mult Scler 18:418-24. 2012
  6. doi request reprint The predictive value of gray matter atrophy in clinically isolated syndromes
    M Calabrese
    Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Via Giustiniani 5, 35128 Padova, Italy
    Neurology 77:257-63. 2011
  7. doi request reprint Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis
    F Rinaldi
    The Multiple Sclerosis Centre of Veneto Region, Department of Neurology, University Hospital of Padova, Italy
    Mult Scler 18:1760-7. 2012
  8. doi request reprint Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population
    M Calabrese
    Multiple Sclerosis Centre of Veneto Region First Neurology Clinic, Department of Neurosciences, University Hospital of Padua, Italy
    AJNR Am J Neuroradiol 33:1507-11. 2012
  9. doi request reprint Widespread cortical thinning characterizes patients with MS with mild cognitive impairment
    M Calabrese
    Department of Neurosciences, University Hospital of Padova, Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, 35128 Padova, Italy
    Neurology 74:321-8. 2010
  10. doi request reprint Increased incidence of multiple sclerosis in the Veneto region, Italy
    M Puthenparampil
    The Multiple Sclerosis Centre of the Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Italy
    Mult Scler 19:601-4. 2013

Collaborators

Detail Information

Publications12

  1. doi request reprint Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis
    Francesca Rinaldi
    Multiple Sclerosis Centre of Veneto Region of Italy, Department of Neuroscience, University Hospital of Padova, Padova, Italy
    Mult Scler 15:1359-62. 2009
    ..We suggest that relapsing-remitting MS patients having had a recent relapse should be treated with natalizumab only after achieving complete clinical and radiological remission...
  2. doi request reprint Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report
    F Rinaldi
    Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Via Giustiniani 5, 35128, Padua, Italy
    Neurol Sci 31:317-20. 2011
    ..Our findings indicate a relevant activity of natalizumab against cortical inflammation in RRMS...
  3. doi request reprint Cortical lesions and cognitive impairment in multiple sclerosis
    F Rinaldi
    Department of Neurosciences, The Multiple Sclerosis Centre of Veneto Region, University Hospital of Padova, Padua, Italy
    Neurol Sci 31:S235-7. 2010
    ....
  4. doi request reprint Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study
    M Calabrese
    Multiple Sclerosis Centre, First Neurology Clinic, University of Padova, Via Giustiniani 5, Padova 35128, Italy
    J Neurol Neurosurg Psychiatry 83:49-54. 2012
    ..The cause of epilepsy in multiple sclerosis (MS) has not yet been elucidated. The relevance of cortical pathology (cortical lesions and thickness) in MS patients with and without epilepsy was evaluated in a longitudinal study...
  5. doi request reprint Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    M Calabrese
    The Multiple Sclerosis Centre of the Veneto Region, Department of Neurology, University Hospital of Padova, Padova, Italy
    Mult Scler 18:418-24. 2012
    ..To measure the effects of disease-modifying drugs (DMDs) on the development of cortical lesions (CL) and cortical atrophy in patients with relapsing-remitting multiple sclerosis (RRMS)...
  6. doi request reprint The predictive value of gray matter atrophy in clinically isolated syndromes
    M Calabrese
    Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Via Giustiniani 5, 35128 Padova, Italy
    Neurology 77:257-63. 2011
    ..Methodologic and clinical constraints may take account for literature discrepancies...
  7. doi request reprint Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis
    F Rinaldi
    The Multiple Sclerosis Centre of Veneto Region, Department of Neurology, University Hospital of Padova, Italy
    Mult Scler 18:1760-7. 2012
    ..Since cortical pathology has been indicated to play a relevant role in the physical and cognitive disability of multiple sclerosis (MS) patients, this study aims to analyze the efficacy of natalizumab in slowing down its progression...
  8. doi request reprint Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population
    M Calabrese
    Multiple Sclerosis Centre of Veneto Region First Neurology Clinic, Department of Neurosciences, University Hospital of Padua, Italy
    AJNR Am J Neuroradiol 33:1507-11. 2012
    ..Thus, we planned a longitudinal study aimed at analyzing and comparing cortical pathology in pediatric and adult MS patients at clinical onset...
  9. doi request reprint Widespread cortical thinning characterizes patients with MS with mild cognitive impairment
    M Calabrese
    Department of Neurosciences, University Hospital of Padova, Multiple Sclerosis Centre of Veneto Region, First Neurology Clinic, 35128 Padova, Italy
    Neurology 74:321-8. 2010
    ..Although cognitive dysfunction affects a relevant portion of patients with multiple sclerosis (MS), its pathologic substrate has not been clarified and it does not seem entirely explained by white matter changes...
  10. doi request reprint Increased incidence of multiple sclerosis in the Veneto region, Italy
    M Puthenparampil
    The Multiple Sclerosis Centre of the Veneto Region, First Neurology Clinic, Department of Neurosciences, University Hospital of Padova, Italy
    Mult Scler 19:601-4. 2013
    ..To what extent the progressive increase in the incidence of multiple sclerosis (MS) observed in the province of Padova over the period 1970-1999 was an expression of a real increased risk of developing MS remained unclear...
  11. doi request reprint Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency
    C Baracchini
    First Neurology Clinic, Department of Neuroscience, University of Padua, Padova, Italy
    Neurology 77:844-50. 2011
    ..Thus, we studied CCSVI prevalence in primary progressive (PP) and secondary progressive (SP) MS, to clarify whether CCSVI characterizes the progressive forms of this disease...
  12. doi request reprint Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification
    A Laroni
    Department of Neuroscience, Ophthalmology and Genetics, University of Genova, Via De Toni 5, 16132, Genoa, Italy
    J Neuroimmune Pharmacol 7:665-72. 2012
    ..In conclusion, testing JCV-DNA in urine is complementary to testing anti-JCV antibodies in identifying patients at risk of PML...